Drug Profile
Research programme: transdermal amfetamine patch - Noven/Takeda
Latest Information Update: 16 Jan 2019
Price :
$50
*
At a glance
- Originator Noven Pharmaceuticals
- Class
- Mechanism of Action Adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Attention-deficit hyperactivity disorder
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 09 Aug 2006 Preclinical trials in Attention-deficit hyperactivity disorder in USA (Transdermal)